The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant
Gene–drug pair / mechanism
CYP3A5
CYP3A5 genotype alters tacrolimus pharmacokinetics: carriers of the CYP3A5*1 allele have lower concentrations and a higher required dose
Summary
Tacrolimus, a first-line immunosuppressant after solid organ transplantation, shows extensive intra- and inter-patient variability and a narrow therapeutic window. Saliva and whole blood samples were collected from 64 children who had received a heart transplant, as part of a tacrolimus PG/PK study. Children carrying a CYP3A5*1 allele required a 2.7-fold higher tacrolimus dose (p < 0.0001) than those with the CYP3A5*3/*3 genotype. Weight-adjusted dose-normalised concentrations of tacrolimus (p < 0.0001) and of its M-I (p = 0.0049) and M-II (p = 0.0043) metabolites are lower in CYP3A5*1 carriers.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
A 2.7-fold difference in dose is clinically telling, and the population, children after heart transplant, is specific. But 64 children and a design that the abstract does not specify limit the reach: the authors themselves call for larger studies before concluding on the clinical importance of the genotype for dosing. To be read as a targeted confirmation, not as a paediatric dosing rule.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 5/10
Keywords
More articles on CYP3A5
Every Wednesday · Annotated selection · Free · Unsubscribe anytime